Caris Life Sciences was founded in 1996 by David Halbert. After raising $130 million in fresh capital in 2021, CFO Thomas Parker told reporters that the company is considering an IPO. "The size of the company’s scale, our future pipeline — some of those things — are pretty well suited for the public markets," he said. "We're taking a serious look at that this year. That doesn’t mean we have definite plans."

Caris Life Sciences is a medical technology company that specializes in molecular profiling, using AI to guide personalized cancer treatments. In 2021, the company announced an $830 million growth equity round, bringing its total funding to $1.3 billion. Investors include Sixth Street Partners, Canada Pension Plan Investment Board, ClearBridge Investments, and Coatue Management. Caris announced a post-money valuation of $7.83 billion.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Caris Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Caris Life Sciences's ticker symbol?

Caris Life Sciences does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Caris Life Sciences's stock price?

The stock price for Caris Life Sciences will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Caris Life Sciences's major investors?

Coatue Management
Fidelity Management & Research
T. Rowe Price
ClearBridge
Neuberger Berman
Silver Lake
Rock Springs Capital
Sixth Street Partners
Millennium Management
OrbiMed
J.H. Whitney Capital Partners

Learn more about Caris Life Sciences

Forge green plus iconForge green minus icon

What is Caris Life Sciences funding to date?

Caris Life Sciences has raised $465MM to date.
Forge green plus iconForge green minus icon

When was Caris Life Sciences founded?

Caris Life Sciences was founded in 2008.
Forge green plus iconForge green minus icon

Can you invest in Caris Life Sciences?

Caris Life Sciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Caris Life Sciences share pre-IPO?

If you own Caris Life Sciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Caris Life Sciences a publicly traded company?

Caris Life Sciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Caris Life Sciences in the Healthcare sector

Sector
Last Round Est. Valuation
$3.45B
Sector
Last Round Est. Valuation
$656.14MM
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$705.25MM
Sector
Last Round Est. Valuation
$1.15B
Sector
Last Round Est. Valuation
$1.22B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Updated on: Jan 23, 2023